皮膚科薬の世界市場 - 市場考察、競合情勢、市場予測（2030年）

世界の皮膚科薬の市場規模は、2030年までに308億8,013万米ドルに達すると予測され、2024年～2030年の予測期間にCAGRで10.62%の成長が見込まれます。市場は、世界中でさまざまな皮膚科疾患の負担が増加していることから、大きな成長を示しています。さらに、人々の皮膚の健康に対する意識の高まり、スキンケアやパーソナルケアへの支出の増加、皮膚疾患にかかりやすい高齢患者の負担の急増、にきびやその他の思春期関連の皮膚疾患にかかりやすい思春期層の増加などが、今後数年間の市場の牽引に寄与する見込みです。したがって、市場は2024年～2030年の予測期間に大幅なCAGRで成長すると予測されます。

皮膚科薬の市場力学

皮膚科薬市場を牽引する重要な側面の1つは、世界中で多数の皮膚疾患の負担が増加していることです。例えば、にきび、肝斑、小じわ、しわなどの皮膚問題に対する関心の高まりは、市場の主な成長促進要因です。人口の増加に伴い、より多くの人々が思春期を迎え、ホルモンや身体の変化の結果として、ニキビ、にきび、顔の赤みなどの特定の皮膚問題に直面します。にきびは、一時的または永久的な傷跡、否定的な自己イメージ、不安を引き起こし、人々の間でさまざまな皮膚科薬の検討につながります。

さらに、皮膚の健康に対する一般の人々の意識の高まりが、皮膚科薬の市場成長を後押ししています。有名人の文化、ソーシャルメディア、美人コンテスト、フィルム、美容広告などの影響により、女性は透明感のある健康的で魅力的な肌を求めており、これらの要因はすべて皮膚科薬市場にプラスの影響を与えています。

National Organization for Rare Disordersが行った最新の調査によると、先天性パキオニキア（PC）という稀な角化性皮膚疾患の有病率は、2021年に世界で5,000～1万人になると報告されています。従って、このような皮膚疾患症例の増加により、関連薬剤の需要が高まると予測されます。

さらに、老年人口の増加も皮膚科薬市場の成長促進要因の1つです。世界保健機関（WHO）の2021年の発表によると、世界の人々の高齢化は加速しており、2050年までに世界人口の80％が高齢者となります。年齢が上がるにつれて、シワ、たるみ、シミ、肌荒れなどの皮膚問題が他の人よりも徐々に起こりやすくなります。そのため、ラパマイシンなどの皮膚科薬によるアンチエイジング治療を選ぶ人が多く、皮膚科薬市場全体のシェアが拡大しています。

主要企業による戦略的活動の増加、製品の承認や上市の増加は、市場における皮膚科薬の需要を増加させています。例えば2024年1月、LEO Pharma ASはTimber Pharmaceuticalsから戦略的資産TMB-001とその他の資産を買収したと発表しました。TMB-001は、アンメットニーズの高い先天性魚鱗癬の複数の中等度から重度のサブタイプに対する局所治療薬を開発しています。また、2023年2月、Pfizerは米国食品医薬品局（FDA）より、中等度から重度のアトピー性皮膚炎（AD）の青少年を対象として、その他の全身治療薬が適切でない、または推奨されない場合にアブロシチニブの使用を拡大するための追加新薬承認申請（sNDA）の承認を取得しました。

したがって、上記のすべての要因が総合的に、2024年～2030年の予測期間を通じて皮膚科薬市場全体を牽引する見込みです。

しかし、医薬品開発コストの高さ、皮膚科薬の副作用、規制当局の厳しい承認プロセスのタイムラインは、皮膚科薬の市場成長を止める可能性があります。

北米は皮膚科薬市場全体を独占すると予測されます。

全地域の中で、北米が2023年に皮膚科薬市場を独占し、2024年～2030年の予測期間にも同様である見込みです。これは、にきび、アトピー性皮膚炎、乾癬、酒さなどのさまざまな皮膚疾患の有病率が上昇しているため、患者の間で皮膚科薬の需要が増加しているためです。さらに、一般用医薬品（OTC）としての皮膚科薬の増加、ジェネリック医薬品に対する需要の急増、スキンケアに対する意識の高まり、主要国内企業のプレゼンス、同地域における製品の上市と承認の増加などが、北米の皮膚科薬市場の成長に寄与しています。

当レポートでは、世界の皮膚科薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 皮膚科薬市場レポートのイントロダクション

第2章 皮膚科薬市場のエグゼクティブサマリー

• 市場の概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 皮膚科薬市場の主な要因の分析

• 皮膚科薬市場の促進要因
• 皮膚科薬市場の抑制要因と課題
• 皮膚科薬市場の機会

第6章 皮膚科薬市場のポーターのファイブフォース分析

第7章 皮膚科薬市場の評価

• 薬剤クラス別
  • 抗感染症薬
  • コルチコステロイド
  • にきび予防
  • カルシニューリン阻害薬
  • レチノイド
  • その他
• 適応症別
  • 脱毛症
  • ヘルペス
  • 乾癬
  • 酒さ様皮膚炎
  • アトピー性皮膚炎
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 皮膚科薬市場の企業と製品のプロファイル

• Amgen Inc
• Bausch Health Companies Inc
• Novartis AG
• AbbVie Inc
• Almirall, S.A
• Bristol-Myers Squibb Company
• Sanofi
• GALDERMA
• GSK plc
• Pfizer Inc
• LEO Pharma AS
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.
• Aclaris Therapeutics, Inc
• Lupin

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Dermatological Drugs Market in Global (2021-2030)
• Table 3: Dermatological Drugs Market in Global by Drug Class (2021-2030)
• Table 4: Dermatological Drugs Market in Global by Indication (2021-2030)
• Table 5: Dermatological Drugs Market in Global by Geography (2021-2030)
• Table 6: Dermatological Drugs Market in North America (2021-2030)
• Table 7: Dermatological Drugs Market in the United States (2021-2030)
• Table 8: Dermatological Drugs Market in Canada (2021-2030)
• Table 9: Dermatological Drugs Market in Mexico (2021-2030)
• Table 10: Dermatological Drugs Market in Europe (2021-2030)
• Table 11: Dermatological Drugs Market in France (2021-2030)
• Table 12: Dermatological Drugs Market in Germany (2021-2030)
• Table 13: Dermatological Drugs Market in United Kingdom (2021-2030)
• Table 14: Dermatological Drugs Market in Italy (2021-2030)
• Table 15: Dermatological Drugs Market in Spain (2021-2030)
• Table 16: Dermatological Drugs Market in the Rest of Europe (2021-2030)
• Table 17: Dermatological Drugs Market in Asia-Pacific (2021-2030)
• Table 18: Dermatological Drugs Market in China (2021-2030)
• Table 19: Dermatological Drugs Market in Japan (2021-2030)
• Table 20: Dermatological Drugs Market in India (2021-2030)
• Table 21: Dermatological Drugs Market in Australia (2021-2030)
• Table 22: Dermatological Drugs Market in South Korea (2021-2030)
• Table 23: Dermatological Drugs Market in Rest of Asia-Pacific (2021-2030)
• Table 24: Dermatological Drugs Market in the Rest of the World (2021-2030)
• Table 25: Dermatological Drugs Market in the Middle East (2021-2030)
• Table 26: Dermatological Drugs Market in Africa (2021-2030)
• Table 27: Dermatological Drugs Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Dermatological Drugs Market in Global (2021-2030)
• Figure 3: Dermatological Drugs Market in Global by Drug Class (2021-2030)
• Figure 4: Dermatological Drugs Market in Global by Indication (2021-2030)
• Figure 5: Dermatological Drugs Market in Global by Geography (2021-2030)
• Figure 6: Dermatological Drugs Market in North America (2021-2030)
• Figure 7: Dermatological Drugs Market in the United States (2021-2030)
• Figure 8: Dermatological Drugs Market in Canada (2021-2030)
• Figure 9: Dermatological Drugs Market in Mexico (2021-2030)
• Figure 10: Dermatological Drugs Market in Europe (2021-2030)
• Figure 11: Dermatological Drugs Market in France (2021-2030)
• Figure 12: Dermatological Drugs Market in Germany (2021-2030)
• Figure 13: Dermatological Drugs Market in United Kingdom (2021-2030)
• Figure 14: Dermatological Drugs Market in Italy (2021-2030)
• Figure 15: Dermatological Drugs Market in Spain (2021-2030)
• Figure 16: Dermatological Drugs Market in the Rest of Europe (2021-2030)
• Figure 17: Dermatological Drugs Market in Asia-Pacific (2021-2030)
• Figure 18: Dermatological Drugs Market in China (2021-2030)
• Figure 19: Dermatological Drugs Market in Japan (2021-2030)
• Figure 20: Dermatological Drugs Market in India (2021-2030)
• Figure 21: Dermatological Drugs Market in Australia (2021-2030)
• Figure 22: Dermatological Drugs Market in South Korea (2021-2030)
• Figure 23: Dermatological Drugs Market in Rest of Asia-Pacific (2021-2030)
• Figure 24: Dermatological Drugs Market in the Rest of the World (2021-2030)
• Figure 25: Dermatological Drugs Market in the Middle East (2021-2030)
• Figure 26: Dermatological Drugs Market in Africa (2021-2030)
• Figure 27: Dermatological Drugs Market in South America (2021-2030)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Dermatological Drugs Market by Drug Class (Anti-Infectives, Corticosteroids, Anti-Acne, Calcineurin Inhibitors, Retinoids, and Others), Indication (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of dermatological disorders such as acne, alopecia areata, psoriasis, atopic dermatitis, rosacea, among others and with the increasing research & development activities in dermatological drugs across the globe

The dermatological drugs market will grow at a CAGR of 10.62% during the forecast period from 2024 to 2030 to reach USD 30,880.13 million by 2030. The dermatological drugs market is observing significant growth due to the growing burden of various dermatological disorders across the globe. Moreover, the rising awareness of skin health among people, their growing expenditure on skincare and personal care, the surging burden of geriatric patients prone to dermatological disorders, and the increasing number of adolescent groups prone to acne and other puberty-related skin disorders will contribute towards driving the market of dermatological drugs in the upcoming years. Therefore, the market for dermatological drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Dermatological Drugs Market Dynamics:

One of the key aspects driving the dermatological drugs market is the rising burden of numerous skin disorders across the globe. For example, the growing concern about skin problems such as acne, melasma, fine lines, and wrinkles is a significant factor driving the growth of the dermatological drugs market. As the population grows, more people reach adolescence, where they face certain skin issues such as pimples, acne, and redness on the face, among others, as a result of hormonal and bodily changes. Acne causes temporary or permanent scarring, a negative self-image, and anxiety, which leads to the consideration of various dermatological drugs among people.

Moreover, the increasing awareness among the public about their skin health will aid in supporting the market growth of dermatological drugs. Owing to the influence of celebrity culture, social media, beauty pageants, movies, beauty advertisements, and other factors, women's desire for clear, healthy, and attractive-looking skin, all the factors positively impact the dermatological drugs market.

According to the latest study done by the National Organization for Rare Disorders, prevalence of Pachyonychia congenita (PC), a rare keratinizing skin disorder was reported to be between 5,000 and 10,000 in 2021, worldwide. Thus, associated drugs are expected to be in high demand, owing to the increasing number of such dermatological disease cases.

Further, the growing geriatric population is another driver for the dermatological drugs market growth. According to the World Health Organization (WHO) 2021, the world population is aging at a faster phase, and by 2050 there will be 80% of aged people living worldwide. The increasing age makes people more prone to skin problems like wrinkles, saggy skin, blemishes, and rough skin among other issues more gradually than others. Thus, these large number of people opting for anti-aging treatment by dermatological drugs such as Rapamycin and others eventually ensures the increasing overall market share for dermatological drugs.

The increasing strategic activities by the key players, rising product approvals, and launches are increasing the demand for dermatological drugs in the market. For instance, in January 2024, LEO Pharma AS announced acquisitions of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals. It develops a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis - a skin disease with significant unmet need. Also, in February 2023, Pfizer Inc. received the US Food and Drug Administration (FDA) approval for supplemental new drug application (sNDA) to expand the use of abrocitinib, for adolescents with moderate to severe atopic dermatitis (AD) when other systemic drug products are not adequate or advisable.

Therefore, all the factors stated above collectively are expected to drive the overall dermatological drugs market throughout the forecast period from 2024 to 2030.

However, the high cost of drug development, the side effects of dermatological drugs, and the timeline of stringent regulatory approval process may halt the market growth of dermatological drugs.

Dermatological Drugs Market Segment Analysis:

Dermatological Drugs Market by Drug Class (Anti-Infectives, Corticosteroids, Anti-Acne, Calcineurin Inhibitors, Retinoids, and Others), Indication (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the indication segment of the dermatological drugs market, the psoriasis category is expected to have a significant revenue share in the year 2023. This is primarily owing to the increasing cases of psoriasis across the globe. Also, the rising launches, strategic investments, and other activities by key players related to the segment will support in driving the market during the forecast period.

According to the National Psoriasis Foundation (2022), about 125 million people were living with psoriasis across the globe. Also, as per the same source, it was stated that 30 percent of people with psoriasis also developed psoriatic arthritis. Additionally, patients with psoriasis incurred annual healthcare costs that are substantially higher than those of the general population. Therefore, from all the above-stated statistics, this category is slated to witness a profitable revenue share in the dermatological drug market and hence promote its overall market growth.

Further, various strategic steps by key players in the market will help in increasing the demand for dermatologicals. For instance, in February 2021, Bristol Myers Squibb Company announced positive results from POETYK PSO-2, the second pivotal Phase III clinical trial evaluating deucravacitinib, a novel, selective tyrosine kinase 2 inhibitor for the treatment of patients with moderate to severe plaque psoriasis. POETYK PSO-2 evaluated deucravacitinib 6 mg once daily and met both co-primary endpoints with significantly more patients achieving Psoriasis Area and Severity Index (PASI 75). Thus, the presence of such psoriasis-treating dermatological drugs in the pipeline may create lucrative growth opportunities for key players in expanding their market and thus in driving the dermatological drugs market during the forecast period.

Thus, owing to all the above-mentioned factors, the demand for psoriasis-treating dermatological drugs upsurges, thereby the category is expected to witness significant growth eventually contributing to the overall growth of the dermatological drugs market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall dermatological drugs market:

Among all the regions, North America is expected to dominate the dermatological drugs market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This can be ascribed to the increasing demand for dermatological drugs in the region owing to its increasing demand among the patients due to the rising prevalence of various dermatological disorders such as acne, atopic dermatitis, psoriasis, rosacea, and others. Further, the increasing number of dermatological drugs as over the counter (OTC), surging demand for generic drugs, the rising awareness about skincare, the presence of key domicile players, rising product launches and approvals in the region, and others are contributing to the growth of the dermatological drugs market in North America.

According to the American Academy of Dermatology Association 2022, about 9,500 people are diagnosed with skin cancer daily in the US and around 3 million non-melanoma skin cancer (NMSC) are estimated to be reported annually. Melanoma is the deadliest form of skin cancer which is growing severely in North America. Various dermatological drugs are used to manage melanoma, ultimately responsible for the surged demand for dermatological drugs.

Furthermore, various domicile players are conducting clinical trials on dermatological drugs, which will create an opportunity for the market to grow in the upcoming years. For instance, In October 2023, Janssen Pharmaceuticals, Inc., a Johnson & Johnson company announced that the recent Phase 3b topline results from Cohort A of the VISIBLE trial, the first prospective, large-scale, randomized-controlled study, focused on evaluating TREMFYA (guselkumab) in patients with moderate to severe plaque psoriasis and scalp psoriasis across all skin tones. At week 16, the trial objectively measured clearance and other treatment outcomes, demonstrating significant efficacy of TREMFYA(R) in achieving these clinical endpoints. This trial underscores the therapeutic potential of guselkumab in a diverse patient population, highlighting its role in the comprehensive management of psoriasis. Therefore, owing to such studies carried out by key players in the region, it may generate future opportunities thereby leading to a notable growth in the dermatological drugs market in North America.

In addition, in October 2023, Ortho Dermatologics received the United States Food and Drug Administration (FDA) approval for IDP-126 gel (CABTREO; clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%, for the topical treatment of acne vulgaris.

Thus, due to the interplay of all the above-mentioned factors, it will lead to an increase in North America dermatological drugs market growth during the forecast period from 2024 to 2030.

Dermatological Drugs Market Key Players:

Some of the key market players operating in the Dermatological Drugs market include Amgen Inc, Bausch Health Companies Inc, Novartis AG, AbbVie Inc, Almirall, S.A, Bristol-Myers Squibb Company, Sanofi, GALDERMA, GSK plc, Pfizer Inc, LEO Pharma AS, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd, Aclaris Therapeutics, Inc, Lupin, and others.

Recent Developmental Activities in the Dermatological Drugs Market:

• In March 2024, Journal Medical Corporation announced that the US Food and Drug Administration (FDA) accepted its new drug application (NDA) for DFD-29 (minocycline hydrochloride modified release capsules, 40 mg). The application pertained to the treatment of inflammatory lesions and erythema in adult patients diagnosed with rosacea.
• In June 2023, Pfizer Inc. announced the United States Food and Drug Administration (FDA) approval of ritlecitinib (Litfulo). It is indicated for individuals aged 12 and over with severe alopecia areata.
• In January 2022, Pfizer Inc. announced that the United States Food and Drug Administration (FDA) approved CIBINQO(R) (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable.

Key Takeaways from the Dermatological Drugs Market Report Study

• Market size analysis for current dermatological drugs market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the dermatological drugs market.
• Various opportunities available for the other competitors in the dermatological drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current dermatological drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for dermatological drugs market growth in the coming future?

Target Audience who can be benefited from this Dermatological Drugs Market Report Study

• Dermatological drug providers
• Research organizations and consulting companies
• Dermatological Drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in dermatological drugs
• Various end-users who want to know more about the dermatological drugs market and latest developments in the dermatological drugs market.

Frequently Asked Questions for the Dermatological Drugs Market:

1. What are dermatological drugs?

Dermatology is a branch of medicine that focuses on the diagnosis, prevention, and treatment of skin diseases, including hair and nail problems. Dermatological drugs are medications used to treat skin diseases. Laser therapy, topical, and systemic medications, photodynamic therapy, radiotherapy, vitiligo surgery, and dermatological surgery are all forms of skin treatment. These dermatological drugs are also used in skincare to keep skin features like radiance and healthiness.

2. What is the market for dermatological drugs?

The dermatological drugs market will grow at a CAGR of 10.62% during the forecast period from 2024 to 2030 to reach USD 30,880.13 million by 2030.

3. What are the drivers for the dermatological drugs market?

The dermatological drugs market is slated to witness prosperity owing to the growing burden of dermatological disorders, rising awareness of skin problems especially among the young group, soaring people's spending power on skincare and personal care, the surging burden of geriatric patients prone to dermatological disorders, surging new drug launches and approvals, presence of key players in the market, and others thus creating an exigency for the dermatological drugs market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the dermatological drugs market?

Some of the key market players operating in Dermatological Drugs market include Amgen Inc, Bausch Health Companies Inc, Novartis AG, AbbVie Inc, Almirall, S.A, Bristol-Myers Squibb Company, Sanofi, GALDERMA, GSK plc, Pfizer Inc, LEO Pharma AS, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd, Aclaris Therapeutics, Inc, Lupin, and others.

5. Which region has the highest share in the dermatological drugs market?

North America is expected to dominate the overall Dermatological Drugs market during the forecast period from 2024 to 2030. This is due to the increasing demand for dermatological drugs among the patients in the region due to the increasing prevalence of various dermatological disorders such as acne, atopic dermatitis, psoriasis, rosacea, and others. Further, the increasing number of dermatological drugs as over the counter (OTC), the rising awareness about skincare, and the presence of key domicile players in the region are factors supporting the growth of the North America dermatological drugs market.

Table of Contents

1. Dermatological Drugs Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Dermatological Drugs Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Dermatological Drugs Market Key Factors Analysis

• 5.1. Dermatological Drugs Market Drivers
  • 5.1.1. The growing burden of dermatological disorders
  • 5.1.2. Rising expenditure of people on skincare and personal care
  • 5.1.3. The surging burden of geriatric patients
• 5.2. Dermatological Drugs Market Restraints and Challenges
  • 5.2.1. High cost of drug development
  • 5.2.2. Side effects of dermatological drugs
  • 5.2.3. The timeline of the stringent regulatory approval process may halt
• 5.3. Dermatological Drugs Market Opportunities
  • 5.3.1. Availability of a robust product portfolio of dermatological drugs in various emerging countries

6. Dermatological Drugs Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Dermatological Drugs Market Assessment

• 7.1. By Drug Class
  • 7.1.1. Anti-infectives
  • 7.1.2. Corticosteroids
  • 7.1.3. Anti-acne
  • 7.1.4. Calcineurin Inhibitors
  • 7.1.5. Retinoids
  • 7.1.6. Others
• 7.2. By Indication
  • 7.2.1. Alopecia
  • 7.2.2. Herpes
  • 7.2.3. Psoriasis
  • 7.2.4. Rosacea
  • 7.2.5. Atopic Dermatitis
  • 7.2.6. Others
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.1.2. Canada Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.1.3. Mexico Dermatological Drugs Market Size in USD million (2021-2030)
  • 7.3.2. Europe
    • 7.3.2.1. France Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.2.2. Germany Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.2.3. United Kingdom Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.2.4. Italy Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.2.5. Spain Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.2.6. Rest of Europe Dermatological Drugs Market Size in USD million (2021-2030)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.3.2. Japan Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.3.3. India Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.3.4. Australia Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.3.5. South Korea Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.3.6. Rest of Asia-Pacific Dermatological Drugs Market Size in USD million (2021-2030)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.4.2. Africa Dermatological Drugs Market Size in USD million (2021-2030)
    • 7.3.4.3. South America Dermatological Drugs Market Size in USD million (2021-2030)

8. Dermatological Drugs Market Company and Product Profiles

• 8.1. Amgen Inc
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Bausch Health Companies Inc
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Novartis AG
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. AbbVie Inc
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Almirall, S.A
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Bristol-Myers Squibb Company
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Sanofi
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. GALDERMA
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. GSK plc
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Pfizer Inc
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. LEO Pharma AS
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Eli Lilly and Company
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Sun Pharmaceutical Industries Ltd.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Aclaris Therapeutics, Inc
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Lupin
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us